Biomaterial Database

[Pharmacokinetic and clinical evaluations on ceftriaxone in neonates and premature infants]. 1988

H Shiro, and Y Kusumoto, and Y Satoh, and T Oikawa, and M Osano

Department of Pediatrics, School of Medicine, Keio University.

Ceftriaxone (CTRX) was clinically evaluated and its pharmacokinetics studied in neonates and premature infants, and the results obtained are summarized as follows. 1. Average blood levels of CTRX after intravenous administration of 10 mg/kg in 3 neonates with birth weights of 2,500 g or more were 45.32 mcg/ml at 15 minutes, 28.91 mcg/ml at 1 hour, 15.76 mcg/ml at 6 hours, and 16.28 mcg/ml at 12 hours, and the half-life was 9.93 hours. The half-life in a newly born premature infant (less than 1 day) was 28.90 hours, and in a premature infant 6 days old it was 12.90 hours. 2. Average blood levels after intravenous administration of 20 mg/kg to 2 neonates aged 0 and 3 days with birth weights of 2,500 g or more, were 129.7 mcg/ml at 15 minutes, 60.94 mcg/ml at 1 hour, 32.04 mcg/ml at 6 hours, and 24.23 mcg/ml at 12 hours, and the half-life was 8.95 hours. The half-life in a newly born premature infant (less than 1 day) was 20.70 hours. 3. Urinary recovery rates of CTRX in 12 hours after intravenous administration of 10 or 20 mg/kg to 6 neonates aged 0 to 3 days (including premature infants) ranged from 13.8 to 50.6%. 4. Clinical efficacies of CTRX were excellent or good in 3 of 4 neonates including infants suspected of having infections (efficacy rate: 75%). 5. As a side effect, diarrhea was noted in 1 case.

UI	MeSH Term	Description	Entries
D007231	Infant, Newborn	An infant during the first 28 days after birth.	Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D007234	Infant, Premature	A human infant born before 37 weeks of GESTATION.	Neonatal Prematurity,Premature Infants,Preterm Infants,Infant, Preterm,Infants, Premature,Infants, Preterm,Premature Infant,Prematurity, Neonatal,Preterm Infant
D007275	Injections, Intravenous	Injections made into a vein for therapeutic or experimental purposes.	Intravenous Injections,Injection, Intravenous,Intravenous Injection
D008297	Male		Males
D002443	Ceftriaxone	A broad-spectrum cephalosporin antibiotic and cefotaxime derivative with a very long half-life and high penetrability to meninges, eyes and inner ears.	Benaxona,Cefatriaxone,Cefaxona,Ceftrex,Ceftriaxon,Ceftriaxon Curamed,Ceftriaxon Hexal,Ceftriaxona Andreu,Ceftriaxona LDP Torlan,Ceftriaxone Irex,Ceftriaxone Sodium,Ceftriaxone Sodium, Anhydrous,Ceftriaxone, Disodium Salt,Ceftriaxone, Disodium Salt, Hemiheptahydrate,Lendacin,Longacef,Longaceph,Ro 13-9904,Ro-13-9904,Ro13-9904,Rocefalin,Rocefin,Rocephin,Rocephine,Tacex,Terbac,Anhydrous Ceftriaxone Sodium,Ro 13 9904,Ro 139904,Ro13 9904,Ro139904
D004341	Drug Evaluation	Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals.	Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260	Female		Females
D006207	Half-Life	The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity.	Halflife,Half Life,Half-Lifes,Halflifes
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001424	Bacterial Infections	Infections by bacteria, general or unspecified.	Bacterial Disease,Bacterial Infection,Infection, Bacterial,Infections, Bacterial,Bacterial Diseases